Candel Therapeutics announces publication of Phase 1b trial data on CAN-2409

Candel Therapeutics (CADL) announced the publication of a manuscript reporting the results of a phase 1b clinical trial exploring safety and tolerability of the combination of CAN-2409 plus prodrug and nivolumab, in addition to standard of care, in patients with newly diagnosed high-grade glioma. The study, which includes evidence of clinical activity and extensive biomarker analysis, has been published online in Neuro-Oncology, the official journal of the Society for Neuro-Oncology. The publication, titled “A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma,” demonstrates that the addition of CAN-2409 and nivolumab and standard of care was generally well tolerated and extended survival in a subset of patients with evidence of local and systemic immune activation after experimental treatment. The clinical trial enrolled 41 patients, with 35 completing the full treatment regimen, and assayed tumor and blood for genetic and immunological biomarkers before and during treatment.